Release of Bioactive Adeno-Associated Virus from Fibrin Scaffolds: Effects of Fibrin Glue Concentrations

Hannah H. Lee, B.S.,^{1,2} Amgad M. Haleem, M.D.,¹ Veronica Yao, Ph.D.,¹ Juan Li, M.D.,³
Xiao Xiao, Ph.D.,³ and Constance R. Chu, M.D.^{1,2}

Fibrin glue (FG) is used in a variety of clinical applications and in the laboratory for localized and sustained release of factors potentially important for tissue engineering. However, the effect of different fibrinogen concentrations on FG scaffold delivery of bioactive adeno-associated viruses (AAVs) has not been established. This study was performed to test the hypothesis that FG concentration alters AAV release profiles, which affect AAV bioavailability. Gene transfer efficiency of AAV-GFP released from FG was measured using HEK-293 cells. Bioactivity of AAV transforming growth factor-beta1 (TGF- β_1) released from FG was assessed using the mink lung cell assay, and by measuring induction of cartilage-specific gene expression in human mesenchymal stem cells (hMSCs). Nondiluted FG had longer clotting times, smaller pore sizes, thicker fibers, and slower dissolution rate, resulting in reduced release of AAV. AAV release and gene transfer efficiency was higher with 25% and 50% FG than with the 75% and 100% FG. AAV-TGF- β_1 released from dilute-FG transduced hMSCs, resulting in higher concentrations of bioactive TGF- β_1 and greater upregulation of cartilage-specific gene expression compared with hMSC from undiluted FG. This study, showing improved release, transduction efficiency, and chondrogenic effect on hMSC of bioactive AAV-TGF- β_1 released from diluted FG, provides information important to optimization of this clinically available scaffold for therapeutic gene delivery, both in cartilage regeneration and for other tissue engineering applications.

Introduction

THE LIMITED REPAIR potential of articular cartilage contributes to the development of debilitating osteoarthritis, a significant public health challenge.^{1,2} Clinical strategies for management of cartilage pathology have evolved from primarily palliative methods to treat early disease until joint replacement for end stage disease, toward more biologic, joint-conserving measures. These include cartilage reconstruction as in osteochondral graft transplantation,³ and cartilage repair as in bone marrow (BM) stimulation,^{4,5} autologous chondrocyte implantation,⁶ or stem cell implantation.⁷ However, results of cartilage repair procedures have been equivocal, and no single approach has been shown to be superior.^{8,9} Therefore, an important strategy for cartilage repair and tissue engineering is on investigating utilization of bioactive factors and biodegradable scaffolds to promote local, recruited, or transplanted cell proliferation and differentiation within cartilage wounds. Despite the promising results of *in vitro* growth factor application, *in vivo* application has not been

as successful due to the short half-life of these growth factors and the need for high repetitive dosing as well as a costly purification process.

Gene therapy can overcome these obstacles by delivering genes that encode chondrogenic growth factors or inhibitors of cartilage catabolites in various vector constructs. This also provides for a local delivery system that drives the expression of therapeutic molecules over an extended period and overcome the need for repeated administrations or interventions. Gene carriers include plasmids, nonviral vectors, and viral vectors. Although plasmid and nonviral vectors are less toxic, less immunogenic, and easier to prepare, their gene delivery efficiencies are significantly lower compared with viral vectors.¹⁰ Hence, viral vectors are currently considered the most effective agents for *in vivo* gene transfer.¹¹

Viral vectors that have been used in the preclinical setting include adenovirus, adeno-associated virus (AAV),¹² and lentivirus.¹³ AAV is derived from an endemic, nonpathogenic parvovirus. It has the following advantages over other viruses: sustained transgene expression over longer period,¹⁴ reduced potential for host immune response, and the capacity

¹Cartilage Restoration Center, Department of Orthopaedic Surgery and ²Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania.

³Division of Molecular Pharmaceutics, The Eshelman School of Pharmacy, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina.

to transduce both dividing and nondividing cells.¹⁵ After transduction, the viral genome translocates into the target cell nucleus, and the DNA polymerase generates the transducing episome. Numerous serotypes of AAV have been identified, each having different preferential targets. Among the different serotypes, AAV serotype 2 (AAV2) is considered to have the best defined safety profile as it has already been used in clinical trials.¹⁶

There are three general approaches for cartilage viral gene therapy applications: direct, indirect, and hybrid. The direct method involves the injection of viral vectors directly into the articular joint space to transduce local cells. Although long-term persistence of transgene expression has been observed with direct injection of AAV2,¹⁴ most of the transduction occurs in soft tissues and it is difficult to localize the transduction to specific cell types. Further, rapid dispersion of viral particles from the joint space would prevent effective transduction of repair cells that are recruited to the defect site over time. Thus, the *in vivo* transduction efficiency remains low and nonspecific transduction of adjacent tissues and their transgene expression at undesired sites is usually observed.¹⁵ The indirect approach involves the use of genetically modified cells,¹² and/or biodegradable scaffolds that release genetically modified cells.^{17,18} This leads to the site-specific release of bioactive molecules important in tissue regeneration, though temporary. In addition, this approach requires *ex vivo* manipulation of cultured cells, which faces high barriers with respect to clinical translation. The third hybrid approach involves implantation of biodegradable scaffolds embedded with genetic materials,^{19,20} leading to direct and localized *in situ* delivery of bioactive vectors to the host cells in proximity to the scaffold, as well as the sustained expression of the transgene. Further, scaffolds can act as support for injury-activated repair or progenitor cells, such as BM-derived mesenchymal stem cells (BM-MSCs), to migrate, attach, and differentiate at the defect site. Thus, the hybrid method offers the advantages of site-specific localization, direct transduction of host repair cells, and sustained transgene expression, while limiting the disadvantages of indiscriminate transduction and requirement of *ex vivo* manipulations.

Our group has previously shown that AAV2-transferring growth factor- β 1 (AAV2-TGF- β 1) transduced human MSCs (hMSCs) implanted into a 1.5-mm-diameter osteochondral defect significantly improved cartilage regeneration over 12 weeks *in vivo*.¹² These results demonstrated that AAV2 is a suitable vector for gene delivery to improve the cartilage repair potential of the MSCs. However, although the *ex vivo* gene transfer is effective, the regulatory barriers for using genetically modified cultured human cells for therapeutic purposes clinically are extremely high. In addition, extraction and expansion of MSCs prolong the time before treatment can be applied and are very expensive. Therefore, we have explored the use of biodegradable scaffolds for release and delivery of bioactive substances to host MSCs within cartilage wound.^{21–24}

Fibrin glue (FG) is a natural substance available for human use clinically as a commercial product or readily prepared from plasma for autologous applications.¹⁵ These properties mean that laboratory findings may be more readily translated into potential human clinical applications than similar findings with synthetic polymers. Despite being widely used

in clinical surgical practice as an adhesive and sealant for hemostasis,²⁵ only in recent years has the ability of FG to act as a delivery scaffold received attention.²⁶ Besides being commercially available for sterile applications, it is non-immunogenic, biodegradable, and malleable so that it can be molded into irregular tissue defects. All of these advantages make FG an appealing scaffold for preclinical translational cartilage tissue engineering applications. It has been shown that diluted FG produces a more open fibrin network compared with undiluted FG scaffolds,²⁷ and that FG can act as an efficient scaffold for gene delivery.^{28–30}

In the current study, we investigated the effect of different fibrinogen dilutions during the preparation of FG scaffold on the delivery of AAV2 and their early effects on human BM-MSC (hBM-MSC) chondrogenesis *in vitro*. The aim of this study was to test the hypotheses that diluted FG scaffolds will release more viral particles, result in higher transduction efficiency, and increase the chondrogenic potential of transduced hBM-MSCs.

Materials and Methods

Preparation of FG

Chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. Twenty-four-well plates and 24-well plate inserts were purchased from BD Biosciences (San Jose, CA). Commercially available Tisseel[®] human fibrin sealant (Baxter, Deerfield, IL) was used to construct FG hydrogels. Fibrinogen (100% of the original material concentration, lyophilized human fibrinogen reconstituted in aprotinin fibrinolysis inhibitor) was prepared by serial dilution with phosphate-buffered saline (PBS; Gibco, Carlsbad, CA) into four different concentrations: 25%, 50%, 75%, and 100% fibrinogen. Different dilutions of fibrinogen were subsequently mixed with an equal volume (1:1 volume ratio) of thrombin solution provided in the Tisseel kit (human thrombin 400–625 IU/mL and calcium chloride 36–44 μ mol/mL). The resultant FG constructs were named 25%, 50%, 75%, and 100% FG, according to the fibrinogen dilution before thrombin activation.

Characterization of different FG concentrations

Clotting time. 100 μ L of different fibrinogen dilutions was mixed with 100 μ L Thrombin-CaCl₂ in a 96-well plate to make 25%, 50%, 75%, and 100% FG scaffolds. Change in the turbidity of the FG scaffold solution was immediately measured by a VersaMax UV-Vis spectrophotometer (Molecular Devices, Sunnyvale, CA) at 550 nm wavelength.³¹ The clotting time was defined as the time at which the maximum value was reached in the absorbance curve. Three replicates of each FG scaffold concentrations were examined in this study.

Scanning electron microscopy. Three FG scaffolds constructed from 200 μ L of different fibrinogen dilutions and 200 μ L Thrombin-CaCl₂ were used for scanning electron microscopy (SEM) analysis. After fixation in 2.5% glutaraldehyde for 1 h and rinsing in PBS, FG scaffolds were dehydrated in increasing alcohol concentrations (30%, 50%, 70%, 90%, and 100%) for 15 min each, followed by hexamethyldisilazane for 1 h. Once hexamethyldisilazane was removed, the scaffolds were air-dried for an hour. Each FG

scaffold was coated with an ultra-thin gold layer containing a gold sputter coater for 2 min at 25 mA and observed under an SEM (JSM-6335F; Jeol USA, Inc., Peabody, MA). Two separate images of each scaffold were captured. Pore size diameter and thickness of fibrin fibers were measured for each image using image analysis software, Metamorph 7.6.2.0 (Molecular Devices).

FG dissolution. Wet weight measurement: Different fibrinogen dilutions were mixed with an equal volume of thrombin- CaCl_2 and injected into uncoated 24-well plate inserts with 8 μm pores at 200 μL FG/insert, and incubated at 37°C for 15 min to form hydrogels. The weight of each insert was measured before injection of the fibrinogen/thrombin solutions. Once the FG scaffolds had solidified, 500 μL PBS was added on top of each inserts, and the inserts were placed in a 24-well plate containing 1 mL PBS/well. After incubation at 37°C for 10 min, inserts were removed, PBS aspirated, surface PBS adsorbed by a filter paper, and the initial weight of the hydrogels (W_0) was recorded. FG hydrogels were re-weighed (W_t) every 2 days to estimate the wet weight fraction, which was defined as $(W_0 - W_t)/W_0$. Five replicates of each FG concentration were examined in this study.

Protein dissolution: The conditioned PBS from each well, in which the FG hydrogels were incubated, was also collected at the time of hydrogel wet weight measurement. The amount of the protein dissolved and released into the PBS was measured by UV-Vis spectroscopy (NanoDrop, Wilmington, DE) at 278 nm, which measures the absorbance of the phenyl group of fibrinopeptide proteins. Fresh PBS was used as blank control.

AAV2-CMV-GFP in vitro transduction

AAV2-CMV-GFP-loaded FG preparation. Double-stranded AAV2-GFP with a cytomegalovirus promoter (dsAAV2-eGFP, hereunder referred to as AAV2-CMV-GFP) was prepared as previously described.³² The AAV2 particles were packaged and purified using the adenovirus-free, triple-plasmid transfection method. The titer (vector genome per milliliter [vg/mL]) was determined by viral DNA dot blot method.³³ The stock AAV2-CMV-GFP titer was 3×10^{12} vg/mL.

The AAV2-CMV-GFP vector stock was added to the various fibrinogen preparations (25%, 50%, 75%, and 100%) to obtain a final concentration of 6.25×10^{10} vg/mL. After vortexing for 3 min, the AAV2-CMV-GFP-loaded fibrinogen solutions were mixed with an equal volume of thrombin- CaCl_2 and injected into uncoated 24-well plate inserts with 8 μm pores, at 200 μL /well. After gelation at 37°C for 15 min, prewarmed 500 μL Dulbecco's modified Eagle's medium (DMEM; Gibco)–1% penicillin-streptomycin (Pen-strep; Gibco) was added to each insert. Three replicates of each AAV2-CMV-GFP-loaded FG concentrations were examined in this study.

AAV2-CMV-GFP released from the AAV2-CMV-GFP loaded FGs and their direct transduction of mammalian cells were assessed over 21 days. HEK-293 cells (ATCC, CRL-1573, Manassas, VA) were maintained in DMEM, 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), and 1% Pen-strep at 37°C and 5% CO_2 . Each day, $\sim 2.4 \times 10^6$ cells were seeded onto 24-well plates at a seeding density of

100,000 cells/well and incubated for 24 h, after which the medium was changed to serum-free DMEM–1% Pen-strep. Inserts containing AAV2-CMV-GFP-loaded FGs were placed into the wells of the 24-well plate seeded with HEK-293 cells and incubated for an additional 24 h at 37°C. The medium was placed below and in the inserts to allow migration of AAV2-CMV-GFP from the FG hydrogels to the seeded cells. Photomicrographs of GFP-expressing cells were taken daily using an Olympus DP71 camera (Olympus America, Center Valley, PA) and Nikon Eclipse TE2000-U microscope (Nikon Instruments Inc., Melville, NY). All GFP images presented in Figure 4C–F had the contrast increased by the same value in Adobe Photoshop CS4 (Adobe Systems, Inc., San Jose, CA) to improve the GFP signal for print.

AAV2-CMV-GFP release from FG

Each day, the conditioned serum free medium from each well was collected and preserved at -80°C until analysis. The amount of AAV2-CMV-GFP released into the conditioned medium from AAV2-CMV-GFP-loaded scaffolds was quantified by quantitative polymerase chain reaction (qPCR). All PCRs contained 0.5 μL of conditioned medium in a total volume of 10 μL using a commercially available pre-prepared $2 \times$ real-time TaqMan PCR master mix (Applied Biosystems, Foster City, CA). GFP-specific custom TaqMan forward (GTCCGCCCTGAGCAAAGA) and reverse (TCCAGCAG GACCATGTGATC) primers as well as FAM-labeled probes (CCCAACGAGAAGCG) were used. All qPCRs were performed with an ABI PRISM 7700 Sequence Detection System (Applied Biosystems) according to the following program: 12 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Three replicates of each experimental group were examined in this study.

In vitro transduction of AAV2-CMV-GFP released from FG

Transduction efficiency was quantified using flow cytometry and expressed as percentage of GFP-positive cells. Both AAV2-CMV-GFP-transduced and -nontransduced control cells were trypsinized, washed, and resuspended in 400 μL of PBS with 1% bovine serum albumin and 2% paraformaldehyde (both from Fischer Scientific, Fair Lawn, NJ). Ten thousand events were collected using a BD Biosciences LSR II (BD Biosciences, Franklin Lakes, NJ). The percentage of GFP-positive cells was determined by defining GFP-negative cells and gating out debris with FlowJo 7.6.1 software (Tree Star, Inc., Ashland, OR). Three replicates of each experimental group were examined in this study.

AAV2-CMV-TGF- β_1 in vitro transduction

AAV2-CMV-TGF- β_1 -loaded FG preparation. Double-stranded AAV2-TGF- β_1 with a cytomegalovirus promoter (dsAAV2-TGF- β_1 , hereunder referred to as AAV2-CMV-TGF- β_1) was prepared as previously described³² and purified as described in the section AAV2-CMV-GFP-loaded FG preparation. The stock AAV2-CMV-TGF- β_1 titer was 2.5×10^{12} vg/mL.

The AAV2-CMV-GFP and AAV2-CMV-TGF- β_1 vector stocks were separately added to 50% and 100% fibrinogen preparations to obtain a final concentration of 1.25×10^{11} vg/

mL. After vortexing for 3 min, the AAV2-loaded fibrinogen solutions were mixed with an equal volume of thrombin- CaCl_2 and injected into uncoated six-well plate inserts with 8 μm pores, at 1 mL/well. After gelation at 37°C for 15 min, prewarmed 3 mL chondrogenic medium–High-Glucose DMEM supplemented with 1% Pen-strep, 10^{-7} M dexamethasone, 50 $\mu\text{g}/\text{mL}$ L-ascorbic acid-2-phosphate, 40 $\mu\text{g}/\text{mL}$ proline (MP Biomedicals, Solon, OH), and 1% ITS+ Premix (BD, Franklin Lakes, NJ) was added to each insert. Three replicates of 50% and 100% AAV2-CMV-TGF- β_1 -loaded FGs were examined in this study against the 50% and 100% AAV2-CMV-GFP-loaded FGs.

AAV2-CMV-TGF- β_1 released from the AAV2-CMV-TGF- β_1 -loaded FGs and their direct transductions of hBM-MSCs were assessed. The hBM-MSCs were obtained, maintained, and characterized as previously described.^{34,35} About 4.8×10^6 cells were seeded onto six-well plates at a seeding density of 200,000 cells per well and incubated for 24 h, after which the medium was changed to a chondrogenic medium. Inserts containing AAV2-CMV-GFP-loaded FGs and AAV2-CMV-TGF- β_1 -loaded FGs were placed into the wells of the 6-well plate seeded with hBM-MSCs and incubated for 24 h. The medium was placed below and in the inserts to allow migration of AAV2s from the FG hydrogels to the seeded cells. After the removal of the inserts, the cells were incubated for an additional 48 h at 37°C. The conditioned serum free medium and hBM-MSCs from each well were collected separately and preserved at -80°C until analysis.

In vitro transduction of AAV2-CMV-TGF- β_1 released from FG

The level of TGF- β_1 expression from hBM-MSCs was assessed by determining the level of TGF- β_1 in cell culture supernatant using a commercially available ELISA (R&D Systems, Inc., Minneapolis, MN) according to the manufacturer's description, and using a CCL-64 mink lung-epithelial growth inhibition assay as previously described with slight modification.^{36,37} Briefly, the CCL-64 cell line (ATCC, CRL-1573) was grown in DMEM, 10% fetal bovine serum, and 1% Pen-strep at 37°C in 5% CO_2 . CCL-64 cells were plated at 5,000 cell/well in 96-well plates and cultured in 100 μL of normal growth media for 3 h. The medium was then changed to 100 μL of serum-free DMEM-1% Pen-strep supplemented with 10% of conditioned media from hBM-MSC culture. The plates were incubated at 37°C in 5% CO_2 for 24 h, and then 20 μL reconstituted XTT reagent from *In Vitro* Toxicology Assay Kit (Sigma-Aldrich) was added to each well for 2 h incubation. The absorbance at 450 nm was measured using VersaMax UV-Vis spectrophotometer (Molecular Devices).

Cartilage-specific gene expression was measured from hBM-MSCs by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Total RNA from the collected hBM-MSC samples was extracted using the RNeasy Mini Kit (Qiagen, Valencia CA). The predesigned human *aggrecan* and 18S TaqMan primers were purchased from Applied Biosystems. Human *sox-9* custom forward (TGACCTATCCAAGCGCATTACCCA) and reverse (ATCATCTCCACGCTTGCTCTGAA) primers as well as FAM-labeled probe (AGGCCAACCTTGGCTAAATGGAGCA) were purchased from Integrated DNA Technologies (IDT, Coralville, IA). All samples contained 1 μL of extracted RNA in a total volume of 10 μL using a

commercially available pre-prepared 2 $\times$ real-time TaqMan PCR master mix (Applied Biosystems). All qRT-PCRs were performed with an ABI PRISM 7700 Sequence Detection System (Applied Biosystems) according to the following program: 12 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Relative expression levels normalized to 18S were calculated using the $2^{-\Delta\text{Ct}}$ method.

Statistical analysis

Data are expressed as mean $\pm$ standard error of mean. Statistical analysis was performed using independent samples *t*-test for comparison between two samples (Fig. 5), and one-way independent analysis of variance or one-way repeated measures analysis of variance with *post hoc* Turkey for multiple comparisons (Figs. 1–4) using Statistical Package for Social Studies (SPSS) 17.0 for Windows (IBM, Chicago, IL). The significance level was set as $p < 0.05$.

Results

Clotting time

After activation of the different fibrinogen dilutions with thrombin- CaCl_2 , there was an immediate change in the turbidity of the solution. The clotting time, or the time of maximal turbidity, was dependent on the fibrinogen concentration ($p < 0.001$). Absorbance of the fibrin gel at 550 nm increased with time for all fibrinogen dilutions until it reached a plateau. The clotting time as a function of fibrinogen concentration is displayed in Figure 1. Clotting time of the 100% FG was significantly higher ($p < 0.05$) than the diluted (25%, 50%, and 75%) FG scaffolds. Although there was no significant difference in clotting time between the dilute FG scaffolds, there was an increasing trend in clotting time with increasing FG concentrations.

SEM analysis of the FG hydrogel microstructures

SEM analysis of pore size diameter of the FG scaffolds showed that all four scaffolds had pore size diameters ranging 50–1200 nm. However, there was a denser, hetero-

FIG. 1. Clotting time showed an increasing trend with increasing fibrin glue (FG) concentrations. Clotting time of 100% FG was statistically higher than diluted FGs. Bars represent mean $\pm$ standard error of mean; $n = 3$. * $p < 0.05$ compared with 100% FG.

geneous distribution of pores in the 100% FG (Fig. 2D) compared with the diluted FG hydrogels, which displayed a more homogenous and larger pore size diameters (Fig. 2A–C). The pore size of the 100% FG was significantly smaller in diameter ($p < 0.05$) than those of the diluted FG scaffolds (Fig. 2E). The fiber thickness of the scaffolds, also assessed by SEM, increased with increasing FG concentrations (Fig. 2F). The increases in fiber thickness were significant between scaffolds with different fibrinogen concentrations ($p < 0.001$).

In vitro dissolution of the FG hydrogels

Analysis of *in vitro* FG dissolution in PBS showed a biphasic pattern (Fig. 3A). Wet weight fraction result showed that the dissolution rate is significantly affected by different concentrations of FG scaffolds ($p < 0.001$): 25% and 50% fibrinogen concentrations displayed a significantly higher rate of dissolution than 75% and 100% FG scaffolds. The first spike in dissolution occurred at day 2 for the 25% and 50% FG scaffolds, where the hydrogels lost ~35% and 15% of their initial weight, respectively. This was followed by a second spike at day 8 when the hydrogels lost ~80% of their initial weight. For the 75% and 100% FG scaffolds, the two spikes in dissolution occurred later at days 6 and 12, with loss of 20% and 90% of the initial weight for the respective time points. The pattern of protein release, observed by UV-vis spectroscopy (Fig. 3B), correlates well with the wet weight fraction finding, by being significantly affected by the percentage of fibrinogen ($p < 0.001$). As well, the biphasic pattern of absorbance peaks that reflects most weight dissolution into the conditioned PBS can be noted.

Quantification of the amount of released AAV2-CMV-GFP from FG hydrogels

The amount of AAV2-CMV-GFP released into the conditioned media from the AAV2-CMV-GFP-loaded FG scaffolds is significantly affected by different concentrations of FG scaffolds ($p < 0.001$), and also displays a biphasic pattern (Fig. 4A). The spikes in the amount of AAV2-CMV-GFP released into the media occurred at day 2 and 9 for 25% and 50% FG scaffolds. In contrast, the spikes in the amount of AAV2-CMV-GFP released into the media occurred at day 2 and 15 for 75% and 100% FG scaffolds. Approximation of the area under the curves in Figure 4A suggests that the vector genomes of AAV2-CMV-GFP released into the media from 75% and 100% FG scaffolds were lower than that of 25% and 50% FG scaffolds.

Quantification of mammalian cell transduction efficiency of released AAV2-CMV-GFP

The percentage of GFP-positive cells from transduction of AAV2-CMV-GFP released into the conditioned media from the AAV2-CMV-GFP-loaded FG scaffolds is also significantly affected by different concentrations of FG scaffolds ($p < 0.001$), and showed a biphasic pattern (Fig. 4B). This pattern is similar to those of the FG dissolution (Fig. 3) and AAV2-CMV-GFP release (Fig. 4A). FG scaffolds with 25% and 50% fibrinogen concentrations yielded significantly higher percentage of GFP-positive cells than the 75% and 100% FG scaffolds. There were spikes in the percentage of GFP-positive cells at days 1 and 8 for all FG scaffolds, which correlate with the biphasic release

FIG. 2. Scanning electron microscopy analyses of FG hydrogels. (A–D) SEM photographs of freeze-dried 25%, 50%, 75%, and 100% FGs, respectively. (E) Pore size analysis of the FG cross sections showed that the pore diameter of the 100% FG was significantly lower than those of the diluted FGs. (F) FG fiber thickness analysis showed an increasing trend with increasing concentration of FG. The fiber thickness of each group was statistically different from each other. Bars represent mean $\pm$ standard error of mean; $n = 3$. * $p < 0.05$, # $p < 0.001$.

FIG. 3. *In vitro* FG dissolution. **(A)** Wet weight fraction analysis and **(B)** absorbance at 278 nm, reflecting the amount of phenyl group of fibrinopeptide proteins dissolved in the conditioned phosphate-buffered saline, showed a biphasic dissolution pattern for all FGs. Data markers represent mean $\pm$ standard error of mean; $n=5$. $*p<0.05$ between 25% and 50% FGs and 75% and 100% FGs.

FIG. 4. *In vitro* characterization of adeno-associated viruses serotype 2 (AAV2)-CMV-GFP-loaded FG scaffolds. **(A)** Vector genomes (vg) of AAV2-CMV-GFP released into 1 mL of conditioned media and **(B)** percentage of GFP-positive HEK-293 cells show biphasic AAV2-CMV-GFP release and corresponding spikes in percentage of GFP-positive cells. Data markers represent mean $\pm$ standard error of mean; $n=3$. $*p<0.05$ between 25% and 50% FGs and 75% and 100% FGs. **(C-F)** Fluorescent and bright-field photomicrographs of HEK-293 cells incubated with AAV2-CMV-GFP-loaded 25%, 50%, 75%, and 100% FGs at day 8 correlates with the quantitative findings in A and B.

pattern of high amounts of AAV2-CMV-GFP at these time points (Fig. 4A). Although 75% and 100% FG scaffolds showed similar biphasic spikes in the percentage of GFP-positive cells, the response was significantly lower compared with 25% and 50% FG scaffolds. Photomicrographs of GFP-expressing cells taken daily confirmed quantitative findings by flow cytometry (Fig. 4C–F).

Quantification and functional analysis of TGF- β_1 expression from hBM-MSCs transduced with released AAV2-CMV-TGF- β_1

The amount of TGF- β_1 synthesized by hBM-MSCs and released into the conditioned medium is significantly affected by different concentrations of FG scaffolds (Fig. 5A, B). Cells incubated with 50% FG loaded with AAV2-CMV-TGF- β_1 made 2.5-fold more active-TGF- β_1 than those incubated with 100% FG loaded with AAV2-CMV-TGF- β_1 , ($p=0.017$, Fig. 5A). As well, the conditioned medium from the hBM-MSC culture that was incubated with the 50% FG loaded with AAV2-CMV-TGF- β_1 resulted in greater inhibition of CCL-64 cell proliferation (Fig. 5B), measured via mitochondrial activity ($p=0.002$). The different concentrations of AAV2-CMV-TGF- β_1 -loaded FG scaffolds also affected the cartilage-specific gene expression of the hBM-MSCs (Fig. 5C). Human *sox-9* and *aggrecan* mRNA expressions were significantly higher for 50% FG versus 100% FG ($p=0.049$ and $p=0.009$, respectively). All the results were normalized against values from AAV2-CMV-GFP-loaded FG scaffolds of the same percentage fibrinogen concentration to account for the effects of viral transduction, FG, and endogenous TGF- β_1 production by hBM-MSCs.

Discussion

Tissue engineering scaffolds allow for the delivery of cells or diffusible factors that can act locally to promote tissue regeneration.^{38,39} The combination of gene therapy and tissue engineering offers the potential to direct progenitor cells' proliferation and differentiation into functional tissue replacement.¹⁵ We have previously shown that hMSCs transduced with AAV-TGF- β_1 improved the *in vivo* cartilage repair when the *ex vivo* transduced cells were implanted into osteochondral defects of athymic rats.¹² However, in an effort to move beyond *ex vivo* gene transfer, the current focus of the project is on *in situ* delivery of therapeutic transgenes, such as TGF- β_1 , directly to host MSCs residing in cartilage wounds using biodegradable scaffolds. This strategy can be thought of as "augmenting" microfracture, which is an accepted human clinical standard for treatment of full-thickness cartilage defects.⁴⁰ The goal of this strategy is to induce localized exogenous transgene expression in repair/progenitor cells infiltrating into the scaffold for sustained release of these factors at the site of injury. Strategies that combine scaffolds, drug delivery technology, and gene therapy have the potential to provide more effective tissue regeneration with significant improvements on safety and cost issues compared to currently available therapies.

Although numerous novel synthetic and natural polymers have been investigated for cartilage tissue engineering studies,^{21,23,24} usage of an FDA-approved and autologous biomaterial as an AAV2-releasing scaffold can accelerate the transition of basic science research into human clinical studies. FG is a biomaterial widely used in clinical practice and tissue engineering applications. As well, dilute FG has

FIG. 5. *In vitro* characterization of AAV2-CMV-TGF- β_1 -loaded FG scaffolds: (A) Mean fold amount of active transforming growth factor-beta1 (TGF- β_1) released into the conditioned media showed increased production of TGF- β_1 from human bone marrow-derived mesenchymal stem cells (hBM-MSCs) incubated with 50% FG. (B) Mean fold XTT absorbance measurement from CCL-64 cells showed higher TGF- β_1 -mediated growth inhibition in samples incubated with conditioned media from 50% FG. (C) Mean fold human *sox-9* and *aggrecan* mRNA expressions from hBM-MSCs incubated with AAV2-CMV-TGF- β_1 -loaded FG scaffolds showed increased expression of relevant chondrogenic genes in cells incubated with 50% FG. Data were normal-

ized against values from AAV2-CMV-GFP-loaded FG scaffolds of the same percentage fibrinogen concentration to account for the effects of viral transduction, FG, and endogenous TGF- β_1 production by hBM-MSCs. Bars represent mean $\pm$ standard error of mean; $n=3$. * $p<0.05$ between 50% and 100% FGs.

been successfully used to treat cartilage wounds in a pilot human clinical study.²² However, studies on its use as a delivery scaffold for gene vectors are limited, and only adenovirus delivery has been investigated for the delivery of viral vectors.²⁶ FG has been investigated as a delivery scaffold for controlled release of adenovirus in a rabbit ear ulcer model²⁹ and for perivenous adventitial gene transfer,³⁰ and was shown to provide enhanced *in vivo* transgene expression over adenovirus transduction without FG scaffold. For cartilage tissue engineering purposes, FG scaffolds with non-viral copolymer-protected polyethylenimine-DNA vectors achieved sustained release of the gene over 20-day period and successful *in vitro* transfection of human keratinocytes and rabbit articular chondrocytes.²⁸

Nonetheless, FG formulation for AAV2 delivery has not been optimized. The fibrinogen/thrombin concentration in the FG preparation has been shown to affect the structural properties of the scaffold, and in turn influence the proliferation rate and morphology of hMSCs.²⁷ Therefore, alterations in FG scaffold microstructure can influence its function as a delivery scaffold for AAV2. The aim of the current study was to assess, *in vitro*, the structural characteristics of FG hydrogels containing varying fibrinogen concentrations, their AAV2-particles release kinetics, and subsequent transgene expression in target cells for articular cartilage tissue engineering.

Undiluted 100% FG scaffold had longer gelation time compared with diluted scaffolds, which may be explained by data from SEM analysis, which showed that 100% FG scaffolds formed a denser scaffold with smaller pore sizes and thicker fibrin fibers than diluted FG scaffolds. In contrast, diluted FG scaffolds had a more open fibrin network, which was reflected by their shorter clotting times. Consistent with another finding,²⁷ diluted FGs had a more homogenous structure than undiluted 100% scaffold.

FG scaffolds dissolved over time in PBS, which was shown by the decrease in the wet weight over time and by the change in absorbance measurements of the phenyl group of the fibrinopeptide over time. Dissolution of the FG scaffolds coincided with the amount of AAV2-CMV-GFP released into the conditioned media. In addition, both the dissolution of the scaffold and the amount of AAV2-CMV-GFP released into the media occurred in a biphasic burst fashion, consistent with a typical hydrogel bulk-degradation pattern. The burst release pattern of AAV2-CMV-GFP was similar to the percentage of GFP-positive HEK-293 cells. There were more GFP-positive cells when a greater amount of AAV2-CMV-GFP was released into the media. Both the amount of AAV2-CMV-GFP released and the number of GFP-positive cells is higher in wells with 25% and 50% FG scaffolds than in those with 75% and 100% FG scaffolds. In addition to dissolution pattern of the FG scaffold, the more open fibrin network of the 25% and 50% FG scaffolds may contribute to greater release of AAV2-CMV-GFP and the higher percentage of GFP-positive cells compared with 75% and 100% FG scaffolds. These *in vitro* studies showed that commercial strength 100% as well as 75% FGs are less efficient at releasing AAV2 particles, and that dilute 25% and 50% FGs are more effective. Viral particles released from dilute FGs retained the ability to transduce HEK-293 cells up to 17 days *in vitro*.

In contrast to our findings with AAV2, a previous study investigating different concentrations of FG scaffold loaded

with adenovirus had achieved optimal viral releasing properties with the higher fibrinogen concentration.⁴¹ However, this was observed with adenovirus vector and with a diluted thrombin concentration. Compared with adenovirus, AAV is much smaller and has the advantages of improved safety profile and longer transgene persistence.¹⁴ In addition, lower thrombin concentration decreases the rate of fibrin cross-linking.²⁶ Since *in vivo* FG decomposition will be accelerated via plasmin-mediated fibrin degradation in addition to diffusion-mediated dissolution, FGs prepared with undiluted thrombin are more likely to persist and release AAV2 particles longer for animal or human applications.

Although many more dilutions of FG at smaller increments could be studied to further assess the AAV2 release kinetics, especially with lower concentrations of FG, the four dilutions were chosen to support the goal of evaluating FG concentrations potentially useful for *in vivo* clinical applications. As well, FG dilutions of 25% approach the lower limit to achieve a clinically functional scaffold structure.⁴¹ For this reason, 50% and 100% FGs were chosen for subsequent studies with AAV2-CMV-TGF- β_1 .

As our ultimate goal is to develop a localized AAV2 delivery system for cartilage tissue engineering, we further explored the concentrations of 50% and 100% FGs for delivery of AAV2 encoding for a therapeutic gene useful for cartilage regeneration. Transforming growth factor- β_1 (TGF- β_1) has long been shown to consistently induce BM-MSC chondrogenesis *in vitro*.^{34,42} We also have previously shown that implantation of AAV2-CMV-TGF- β_1 -transduced hMSCs into osteochondral defects has improved cartilage repair *in vivo*.¹² Therefore, we compared AAV2-CMV-TGF- β_1 delivery from the 50% and 100% FGs to hBM-MSCs *in vitro*. The studies on FG scaffold delivery of therapeutic-AAVs, versus reporter gene-AAVs, especially for their chondrogenic effects, have been limited to date.²⁶ hBM-MSCs cultured with 50% FG-AAV2-CMV-TGF- β_1 construct had higher concentration of active TGF- β_1 , which resulted in greater inhibition of CCL-64 cell proliferation, and higher cartilage-specific gene expression levels in transduced hBM-MSCs.

In summary, we have demonstrated that varying the fibrinogen concentrations in FG constructs changes the structural and functional characteristics of the scaffold for gene delivery. Diluting the fibrinogen concentration yields a scaffold with a network of larger pores and thinner fibers, which reduces entrapment and subsequently enhances the release of AAV2 particles. Lower concentration FG scaffolds have also been shown to promote greater proliferation for hMSCs, which are the principal cell types recruited for *in situ* chondrogenesis.²⁷ Therefore, implantation of diluted FG scaffolds containing bioactive AAV2 vectors have the potential to improve articular cartilage regeneration and be translated for clinical cartilage tissue engineering. Further *in vivo* studies are planned using small and large animal models to validate the enhanced repair potential of diluted FG scaffolds with therapeutic AAV2-TGF- β_1 for localized *in situ* cartilage tissue engineering before translation into the clinical setting.

Acknowledgments

We thank Kimberlee K. Suter and Judong Lee for technical assistance. Funding for this work was provided by the National Institutes of Health RO1 AR051963 (C.R.C.) and

RC2 AR058929 (C.R.C.). HHL receives partial support from T32 EB001026 (R.P.B.).

Disclosure Statement

No competing financial interests exist.

References

- Cooper, C., Snow, S., McAlindon, T.E., Kellingray, S., Stuart, B., Coggon, D., and Dieppe, P.A. Risk factors for the incidence and progression of radiographic knee osteoarthritis. *Arthritis Rheum* **43**, 995, 2000.
- Lawrence, R.C., Helmick, C.G., Arnett, F.C., Deyo, R.A., Felson, D.T., Giannini, E.H., Heyse, S.P., Hirsch, R., Hochberg, M.C., Hunder, G.G., Liang, M.H., Pillemer, S.R., Steen, V.D., and Wolfe, F. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. *Arthritis Rheum* **41**, 778, 1998.
- Chu, C.R., Convery, F.R., Akeson, W.H., Meyers, M., and Amiel, D. Articular cartilage transplantation. Clinical results in the knee. *Clin Orthop Relat Res* **360**, 159, 1999.
- Kramer, J., Bohrsen, F., Lindner, U., Behrens, P., Schlenke, P., and Rohwedel, J. *In vivo* matrix-guided human mesenchymal stem cells. *Cell Mol Life Sci* **63**, 616, 2006.
- Steadman, J.R., Briggs, K.K., Rodrigo, J.J., Kocher, M.S., Gill, T.J., and Rodkey, W.G. Outcomes of microfracture for traumatic chondral defects of the knee: average 11-year follow-up. *Arthroscopy* **19**, 477, 2003.
- Krishnan, S.P., Skinner, J.A., Carrington, R.W., Flanagan, A.M., Briggs, T.W., and Bentley, G. Collagen-covered autologous chondrocyte implantation for osteochondritis dissecans of the knee: two- to seven-year results. *J Bone Joint Surg Br* **88**, 203, 2006.
- Wakitani, S., Imoto, K., Yamamoto, T., Saito, M., Murata, N., and Yoneda, M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. *Osteoarthritis Cartilage* **10**, 199, 2002.
- Jakobsen, R.B., Engebretsen, L., and Slauterbeck, J.R. An analysis of the quality of cartilage repair studies. *J Bone Joint Surg Am* **87**, 2232, 2005.
- Magnussen, R.A., Dunn, W.R., Carey, J.L., and Spindler, K.P. Treatment of focal articular cartilage defects in the knee: a systematic review. *Clin Orthop Relat Res* **466**, 952, 2008.
- Nishikawa, M., and Huang, L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. *Hum Gene Ther* **12**, 861, 2001.
- Loser, P., Huser, A., Hillgenberg, M., Kumin, D., Both, G.W., and Hofmann, C. Advances in the development of non-human viral DNA-vectors for gene delivery. *Curr Gene Ther* **2**, 161, 2002.
- Pagnotto, M.R., Wang, Z., Karpie, J.C., Ferretti, M., Xiao, X., and Chu, C.R. Adeno-associated viral gene transfer of transforming growth factor-beta1 to human mesenchymal stem cells improves cartilage repair. *Gene Ther* **14**, 804, 2007.
- Caplan, A.I. Mesenchymal stem cells and gene therapy. *Clin Orthop Relat Res* **379 Suppl**, S67, 2000.
- Payne, K.A., Lee, H.H., Haleem, A.M., Martins, C., Yuan, Z., Qiao, C., Xiao, X., and Chu, C.R. Single intra-articular injection of adeno-associated virus results in stable and controllable *in vivo* transgene expression in normal rat knees. *Osteoarthritis Cartilage* 2011. [In press].
- Jang, J.H., Houchin, T.L., and Shea, L.D. Gene delivery from polymer scaffolds for tissue engineering. *Expert Rev Med Devices* **1**, 127, 2004.
- Mueller, C., and Flotte, T.R. Clinical gene therapy using recombinant adeno-associated virus vectors. *Gene Ther* **15**, 858, 2008.
- Gelse, K., von der Mark, K., Aigner, T., Park, J., and Schneider, H. Articular cartilage repair by gene therapy using growth factor-producing mesenchymal cells. *Arthritis Rheum* **48**, 430, 2003.
- Madry, H., Kaul, G., Cucchiari, M., Stein, U., Zurakowski, D., Remberger, K., Menger, M.D., Kohn, D., and Trippel, S.B. Enhanced repair of articular cartilage defects *in vivo* by transplanted chondrocytes overexpressing insulin-like growth factor I (IGF-I). *Gene Ther* **12**, 1171, 2005.
- Capito, R.M., and Spector, M. Collagen scaffolds for nonviral IGF-1 gene delivery in articular cartilage tissue engineering. *Gene Ther* **14**, 721, 2007.
- Guo, T., Zhao, J., Chang, J., Ding, Z., Hong, H., Chen, J., and Zhang, J. Porous chitosan-gelatin scaffold containing plasmid DNA encoding transforming growth factor-beta1 for chondrocytes proliferation. *Biomaterials* **27**, 1095, 2006.
- Ferretti, M., Marra, K.G., Kobayashi, K., Defail, A.J., and Chu, C.R. Controlled *in vivo* Degradation of genipin cross-linked polyethylene glycol hydrogels within osteochondral defects. *Tissue Eng* **12**, 2657, 2006.
- Haleem, A.M., El Singergy, A.A., Sabry, D., Atta, H., Rashed, L.A., Chu, C.R., El Shewy, M.T., Azzam, A., and Abdel Aziz, M.T. The clinical use of human culture-expanded autologous bone marrow mesenchymal stem cells transplanted on platelet-rich fibrin glue in the treatment of articular cartilage defects—a pilot study and preliminary results. *Cartilage* **1**, 253, 2010.
- Tan, H., Chu, C.R., Payne, K.A., and Marra, K.G. Injectable *in situ* forming biodegradable chitosan-hyaluronic acid based hydrogels for cartilage tissue engineering. *Biomaterials* **30**, 2499, 2009.
- Tan, H., DeFail, A.J., Rubin, J.P., Chu, C.R., and Marra, K.G. Novel multiarm PEG-based hydrogels for tissue engineering. *J Biomed Mater Res A* **92A**, 979, 2010.
- Spotnitz, W.D. Fibrin sealant: past, present, and future: a brief review. *World J Surg* **34**, 632, 2010.
- Breen, A., O'Brien, T., and Pandit, A. Fibrin as a delivery system for therapeutic drugs and biomolecules. *Tissue Eng B Rev* **15**, 201, 2009.
- Ho, W., Tawil, B., Dunn, J.C., and Wu, B.M. The behavior of human mesenchymal stem cells in 3D fibrin clots: dependence on fibrinogen concentration and clot structure. *Tissue Eng* **12**, 1587, 2006.
- Schillinger, U., Wexel, G., Hacker, C., Kullmer, M., Koch, C., Gerg, M., Vogt, S., Ueblacker, P., Tischer, T., Hensler, D., Wilisch, J., Aigner, J., Walch, A., Stemmerger, A., and Plank, C. A fibrin glue composition as carrier for nucleic acid vectors. *Pharm Res* **25**, 2946, 2008.
- Breen, A., Dockery, P., O'Brien, T., and Pandit, A. Fibrin scaffold promotes adenoviral gene transfer and controlled vector delivery. *J Biomed Mater Res A* **89**, 876, 2009.
- Wan, L., Li, D., and Wu, Q. Perivenous application of fibrin glue as external support enhanced adventitial adenovirus transfection in rabbit model. *J Surg Res* **135**, 312, 2006.
- Zhao, H., Ma, L., Gong, Y., Gao, C., and Shen, J. A polylactide/fibrin gel composite scaffold for cartilage tissue engineering: fabrication and an *in vitro* evaluation. *J Mater Sci Mater Med* **20**, 135, 2009.
- Rehman, K.K., Wang, Z., Bottino, R., Balamurugan, A.N., Trucco, M., Li, J., Xiao, X., and Robbins, P.D. Efficient gene delivery to human and rodent islets with double-stranded (ds) AAV-based vectors. *Gene Ther* **12**, 1313, 2005.

33. Xiao, X., Li, J., and Samulski, R.J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. *J Virol* **72**, 2224, 1998.
34. Payne, K.A., Didiano, D.M., and Chu, C.R. Donor sex and age influence the chondrogenic potential of human femoral bone marrow stem cells. *Osteoarthritis Cartilage* **18**, 705, 2010.
35. Schugar, R.C., Chirieleison, S.M., Wescoe, K.E., Schmidt, B.T., Askew, Y., Nance, J.J., Evron, J.M., Peault, B., and Deasy, B.M. High harvest yield, high expansion, and phenotype stability of CD146 mesenchymal stromal cells from whole primitive human umbilical cord tissue. *J Biomed Biotechnol* **2009**, 11, 2009.
36. DeFail, A.J., Chu, C.R., Izzo, N., and Marra, K.G. Controlled release of bioactive TGF- β 1 from microspheres embedded within biodegradable hydrogels. *Biomaterials* **27**, 1579, 2006.
37. Wang, X., Chen, Y., Lv, L., and Chen, J. Silencing CD36 gene expression results in the inhibition of latent-TGF- β 1 activation and suppression of silica-induced lung fibrosis in the rat. *Respir Res* **10**, 36, 2009.
38. De Laporte, L., and Shea, L.D. Matrices and scaffolds for DNA delivery in tissue engineering. *Adv Drug Deliv Rev* **59**, 292, 2007.
39. Pannier, A.K., and Shea, L.D. Controlled release systems for DNA delivery. *Mol Ther* **10**, 19, 2004.
40. Mithoefer, K., McAdams, T., Williams, R.J., Kreuz, P.C., and Mandelbaum, B.R. Clinical efficacy of the microfracture technique for articular cartilage repair in the knee. *Am J Sports Med* **37**, 2053, 2009.
41. Breen, A., Strappe, P., Kumar, A., O'Brien, T., and Pandit, A. Optimization of a fibrin scaffold for sustained release of an adenoviral gene vector. *J Biomed Mater Res A* **78A**, 702, 2006.
42. Kawamura, K., Chu, C.R., Sobajima, S., Robbins, P.D., Fu, F.H., Izzo, N.J., and Niyibizi, C. Adenoviral-mediated transfer of TGF- β 1 but not IGF-1 induces chondrogenic differentiation of human mesenchymal stem cells in pellet cultures. *Exp Hematol* **33**, 865, 2005.

Address correspondence to:

Constance R. Chu, M.D.

Department of Orthopaedic Surgery

Cartilage Restoration Center

University of Pittsburgh

Kaufmann Medical Building, Suite 911

3471 Fifth Ave.

Pittsburgh, PA 15213

E-mail: chucr@upmc.edu

Received: October 7, 2010

Accepted: March 28, 2011

Online Publication Date: May 3, 2011